MIRM:NSD-Mirum Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 38.7

Change

-0.29 (-0.74)%

Market Cap

N/A

Volume

0.25M

Analyst Target

USD 48.71
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing MIRM

BBP Virtus LifeSci Biotech Pr.. 2.14 % 0.79 %

+0.58 (+0.53%)

USD 0.02B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

+0.64 (+0.53%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.10% 76% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.10% 76% C+ 84% B
Trailing 12 Months  
Capital Gain 22.62% 69% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.62% 69% C- 67% D+
Trailing 5 Years  
Capital Gain 299.38% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 299.38% 92% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 24.59% 74% C 81% B-
Dividend Return 24.59% 74% C 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.24% 70% C- 44% F
Risk Adjusted Return 59.63% 97% N/A 84% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector